Observational studyEuropean heart journal2020
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.
Observational study in European heart journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 17 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 17 syntheses or guidelines pooled it, 263 citations in OpenAlex.
- Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis.Infection · 2022Pooled it
- Incidence and prognostic value of pulmonary embolism in COVID-19: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials.Journal of thrombosis and haemostasis : JTH · 2021Pooled it
- Venous thromboembolism is linked to severity of disease in COVID-19 patients: A systematic literature review and exploratory meta-analysis.International journal of clinical practice · 2021Pooled it
- Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis.Critical care medicine · 2021Pooled it
- Pulmonary embolism in patients with COVID-19 and value of D-dimer assessment: a meta-analysis.European radiology · 2021Pooled it
- Risk factors for pulmonary embolism in patients with COVID-19: a systemic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019.Journal of vascular surgery. Venous and lymphatic disorders · 2021Pooled it
- Mortality and risk factors associated with pulmonary embolism in coronavirus disease 2019 patients: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Venous thromboembolism in COVID-19: A systematic review and meta-analysis.Vascular medicine (London, England) · 2021Pooled it
- A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy.Shock (Augusta, Ga.) · 2021Pooled it
- Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients.Scientific reports · 2021Pooled it
- Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies.Reviews in medical virology · 2021Pooled it
- Pooled it
- Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis.Thrombosis and haemostasis · 2021Pooled it
- Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis.European journal of internal medicine · 2020Pooled it
- Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies.Therapeutic advances in cardiovascular diseasePooled it
- Multimorbidity and mortality trends in the COVID19 syndemic in Madagascar covering 180 diseases 2015 2024.iScience · 2026Article
- Circulating NET Biomarkers as Predictors of Inflammatory Storm Escalation and Critical Illness in COVID-19.Journal of microbiology and biotechnology · 2025Article
- Predictors of venous thromboembolic events in hospitalized patients with COVID-19.Journal of thrombosis and thrombolysis · 2025Article
101 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
32 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWhile pulmonary embolism (PE) appears to be a major issue in COVID-19, data remain sparse. We aimed to describe the risk factors and baseline characteristics of patients with PE in a cohort of COVID-19 patients. METHODS AND
resultsIn a retrospective multicentre observational study, we included consecutive patients hospitalized for COVID-19. Patients without computed tomography pulmonary angiography (CTPA)-proven PE diagnosis and those who were directly admitted to an intensive care unit (ICU) were excluded. Among 1240 patients (58.1% men, mean age 64 ± 17 years), 103 (8.3%) patients had PE confirmed by CTPA. The ICU transfer and mechanical ventilation were significantly higher in the PE group (for both P < 0.001). In an univariable analysis, traditional venous thrombo-embolic risk factors were not associated with PE (P > 0.05), while patients under therapeutic dose anticoagulation before hospitalization or prophylactic dose anticoagulation introduced during hospitalization had lower PE occurrence [odds ratio (OR) 0.40, 95% confidence interval (CI) 0.14-0.91, P = 0.04; and OR 0.11, 95% CI 0.06-0.18, P < 0.001, respectively]. In a multivariable analysis, the following variables, also statistically significant in univariable analysis, were associated with PE: male gender (OR 1.03, 95% CI 1.003-1.069, P = 0.04), anticoagulation with a prophylactic dose (OR 0.83, 95% CI 0.79-0.85, P < 0.001) or a therapeutic dose (OR 0.87, 95% CI 0.82-0.92, P < 0.001), C-reactive protein (OR 1.03, 95% CI 1.01-1.04, P = 0.001), and time from symptom onset to hospitalization (OR 1.02, 95% CI 1.006-1.038, P = 0.002).
conclusionPE risk factors in the COVID-19 context do not include traditional thrombo-embolic risk factors but rather independent clinical and biological findings at admission, including a major contribution to inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.